-->

Company Registry

Macrochem Corporation (AKA:MCHM)
Profile last edited on: 2/12/2019

Transdermal drug-delivery systems
Year Founded
1981
First SBIR Year
1988
Latest SBIR Award
2001
Program Status
Inactive (Acquired)

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

110 Hartwell Avenue
Lexington, MA 02421
   (781) 862-4003
   info@macrochem.com
   www.macrochem.com
Multiple Locations:   
Congressional District:   05
County:   Middlesex

Public Profile

In July 2008, it was announced that Access Pharmaceuticals would acquire publicly held drug delivery firm MacroChem using the porceeds from sale of its some of own shares of its common stock. In September 2005, Macrochem Corporation (NASDAQ:MCHM) had announced it would end its research and auction off all of its assets. Macrochem had been working in the field of transdermal drug-delivery systems which allow drugs to be absorbed through the skin via creams, gels, patches, and the like. MacroChem ihad been trying to attract business partners by applying its SEPA (Soft Enhancer of Percutaneous Absorption) system to FDA-approved drugs. The company did test its system's use with drugs used to treat impotence (Topiglan), testosterone deficiency, arthritis pain, and skin conditions. MacroChem also developed a delivery with potential applications in cosmetics and other topical products (moisturizers, sunscreens, insect repellents). Ascent Pediatrics has licensed SEPA for possible use in treating allergies and respiratory disorders.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : MCHM
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2001 1 NIH $158,335
Topical Adenosine and Microvascular Changes in Diabetes
1989 1 NIH $50,000
Flouride releasing sealant for caries prevention
1988 1 NIH $50,000
Drug therapy for hypercalcemia/bone resorption

Key People / Management

  John Zabriskie -- President

  Robert J Deluccia -- Former President & CEO

  David P Luci -- VP Corporate Development

  Robert J Palmisano --

  Eugene P Pittz --

  Carlos M Samour --

  Samuel C Temin --

SBIR firms in the news

There are no news available.